# IMU Biosciences

> UK biotech IMU Biosciences extended its oversubscribed Series A past $53M in June 2026 to map and decode the human immune system for drug discovery.

## Why it is interesting

The immune system underlies most disease, yet remains poorly mapped. IMU builds large-scale immune-profiling to turn immune data into actionable diagnostics and therapeutic targets. - Immune dysregulation drives cancer, autoimmunity, and chronic disease. - High-throughput profiling plus AI can finally decode immune complexity. - Pharma needs better targets and patient stratification. UK biotech IMU Biosciences extended its oversubscribed Series A past $53M in June 2026 to map and decode the human immune system for drug discovery.

## Profile

- **Stage:** series-a
- **Status:** private
- **Industries:** ai-ml, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-06-03

## Key facts

- Disclosed financing: $53M (Series A)
- Covered in 1 Venture Capital Tracker article(s)

## Related articles

- https://venturecapitaltracker.com/2026-imu-biosciences-53m-immune-mapping

---
Source: https://venturecapitaltracker.com/startup/imu-biosciences